Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy

Background. Due to the advanced oncological treatments of cancer, an overall increase in cancer incidence, and better diagnostic tools, the incidence of brain metastases is on the rise. This review addresses the current treatment options for patients with multiple brain metastases, presenting electrochemotherapy (ECT) as one of the new experimental treatments for this group of patients. Conclusions. Neurosurgery, stereotactic surgery, and whole-brain radiotherapy are the evidence-based treatments that can be applied for patients with multiple brain metastases. Treatment with chemotherapy and molecularly targeted agents may also be warranted. Several experimental treatments are emerging, one of which is ECT, an effective cancer treatment comprising electric pulses given by electrodes in the tumor tissue, causing electroporation of the cell membrane, and thereby augmenting uptake and the cytotoxicity of the chemotherapeutic drug bleomycin by 300 times. Preclinical data are promising and the first patient has been treated in an ongoing clinical trial for patients with brain metastases. Perspectives for ECT in the brain include treatment of primary and secondary brain tumors as well as soft tissue metastases elsewhere.

[1]  W. Regine,et al.  The Rationale for Adjuvant Whole Brain Radiation Therapy with Radiosurgery in the Treatment of Single Brain Metastases , 2003, Technology in cancer research & treatment.

[2]  D Miklavcic,et al.  Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma , 2008, British Journal of Cancer.

[3]  Sana Intidhar Labidi,et al.  Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. , 2009, Clinical breast cancer.

[4]  Kristine Broglio,et al.  Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma , 2006, Cancer.

[5]  M. Mehta,et al.  Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Thiel,et al.  Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors , 2011, Journal of Neuro-Oncology.

[7]  L. Mir,et al.  Electrochemotherapy, a new antitumor treatment. First clinical phase I‐II trial , 1993, Cancer.

[8]  D. Sharma,et al.  Reirradiation for progressive brain metastases. , 2009, Journal of cancer research and therapeutics.

[9]  J. Berlin,et al.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Faisal Mahmood,et al.  Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. , 2011, Cancer research.

[11]  Carlos Camps,et al.  Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  M. Jaroszeski,et al.  Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin , 1998, Cancer.

[13]  A Brun,et al.  A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. , 1993, Biochemical and biophysical research communications.

[14]  Torben Skovsgaard,et al.  Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. , 2002, Biochimica et biophysica acta.

[15]  P. Sterk,et al.  Long-term effects of chemotherapy in patients with testicular cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Hall,et al.  Brain metastases: Histology, multiplicity, surgery, and survival , 1996 .

[17]  N. Triller,et al.  Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting , 2012, Radiology and oncology.

[18]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.

[19]  M. Mehta,et al.  Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. , 2008, International journal of radiation oncology, biology, physics.

[20]  H. Newton,et al.  Intra-arterial Carboplatin and Intravenous Etoposide for the Treatment of Metastatic Brain Tumors , 2004, Journal of Neuro-Oncology.

[21]  A. Brandes,et al.  Brain metastases from non-small-cell lung cancer: is there room for improvement? , 2012, Expert review of anticancer therapy.

[22]  M J Jaroszeski,et al.  Toxicity of anticancer agents mediated by electroporation in vitro , 2000, Anti-cancer drugs.

[23]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[24]  C. Balch,et al.  Finally, a successful adjuvant therapy for high-risk melanoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Collins,et al.  Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes , 2006 .

[26]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[27]  H. Groesbeck.  Evaluation of routine scintiscanning of nontoxic thyroid nodules. I. The preoperative diagnosis of thyroid carcinoma , 1959, Cancer.

[28]  M. Jenkinson,et al.  Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. , 2011, European journal of cancer.

[29]  D. Kondziolka,et al.  The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[30]  K. Smedby,et al.  Brain metastases admissions in Sweden between 1987 and 2006 , 2009, British Journal of Cancer.

[31]  L. Mir,et al.  Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. , 1988, Biochemical pharmacology.

[32]  P Raskmark,et al.  In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. , 1999, Biochimica et biophysica acta.

[33]  D. Kondziolka,et al.  The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[34]  Julie Gehl,et al.  Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. , 2003, Cancer treatment reviews.

[35]  Julie Gehl,et al.  Bleomycin treatment of brain tumors: an evaluation. , 2009, Anti-cancer drugs.

[36]  M. Caraglia,et al.  Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life , 2007, BMC Cancer.

[37]  M. Hazuka,et al.  Brain metastases: results and effects of re-irradiation. , 1988, International journal of radiation oncology, biology, physics.

[38]  M. Gore,et al.  Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Brown,et al.  Whole-brain radiotherapy in the management of brain metastasis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  V. Guillem,et al.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation , 2010, European Respiratory Journal.

[42]  J. Gehl,et al.  Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs , 1998, Anti-cancer drugs.

[43]  J. Gehl,et al.  Management of cutaneous metastases using electrochemotherapy , 2011, Acta oncologica.

[44]  M. Caraglia,et al.  The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? , 2011, Expert review of anticancer therapy.

[45]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Bucana,et al.  The seed and soil hypothesis: vascularisation and brain metastases. , 2002, The Lancet. Oncology.

[47]  Faisal Mahmood,et al.  Optimizing clinical performance and geometrical robustness of a new electrode device for intracranial tumor electroporation. , 2011, Bioelectrochemistry.

[48]  D. Pectasides,et al.  Late complications of chemotherapy in testicular cancer. , 2010, Cancer treatment reviews.

[49]  V. Kovač,et al.  Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana , 2010, Radiology and oncology.

[50]  Damijan Miklavčič,et al.  Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study , 2006 .

[51]  C. Porta,et al.  Sunitinib in metastatic renal cell carcinoma patients with brain metastases , 2011, Cancer.

[52]  T. Jarm,et al.  Electrochemotherapy , 2011, Technology in cancer research & treatment.

[53]  J. Gehl.  [Investigational treatment of cancer using electrochemotherapy, electrochemoimmunotherapy and electro-gene transfer]. , 2005, Ugeskrift for laeger.

[54]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  N. Viñolas,et al.  Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. , 2005, International journal of radiation oncology, biology, physics.

[56]  D. Antonadou,et al.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. Gennari,et al.  Anthracycline-free therapy for HER2-amplified breast cancer. , 2013, The Lancet. Oncology.

[58]  L. Mir,et al.  The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway , 2001, British Journal of Cancer.

[59]  Armin Thron,et al.  Diagnostic Accuracy of MRI Compared to CCT in Patients with Brain Metastases , 2004, Journal of Neuro-Oncology.

[60]  S. Kalkanis,et al.  Evidence-based guidelines for the management of brain metastases. , 2011, Neurosurgery clinics of North America.

[61]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.